Gwen Weld - Nautilus Biotechnology Chief Officer
| NAUT Stock | USD 1.71 0.06 3.39% |
Insider
Gwen Weld is Chief Officer of Nautilus Biotechnology
| Age | 67 |
| Address | 2701 Eastlake Avenue East, Seattle, WA, United States, 98102 |
| Phone | 206 333 2001 |
| Web | https://www.nautilus.bio |
Gwen Weld Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gwen Weld against Nautilus Biotechnology stock is an integral part of due diligence when investing in Nautilus Biotechnology. Gwen Weld insider activity provides valuable insight into whether Nautilus Biotechnology is net buyers or sellers over its current business cycle. Note, Nautilus Biotechnology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nautilus Biotechnology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gwen Weld over two months ago Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.0 subject to Rule 16b-3 | ||
Gwen Weld over two months ago Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3 |
Nautilus Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.1762) % which means that it has lost $0.1762 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2804) %, meaning that it created substantial loss on money invested by shareholders. Nautilus Biotechnology's management efficiency ratios could be used to measure how well Nautilus Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.23 in 2025. Return On Capital Employed is likely to drop to -0.24 in 2025. Total Current Liabilities is likely to gain to about 11 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 239 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Eric MD | Bioatla | 61 | |
| Deepika PharmD | Pmv Pharmaceuticals | 49 | |
| Kelly Schick | C4 Therapeutics | 45 | |
| Cindy Hayashi | Caribou Biosciences | N/A | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Brian MD | Rezolute | 50 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Derek Jantz | Precision BioSciences | 48 | |
| Yuichi MD | MediciNova | 75 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Brian Riley | Beam Therapeutics | 47 | |
| Nicole Gaudelli | Beam Therapeutics | N/A | |
| DPhil DPHIL | Kymera Therapeutics | 48 | |
| Hing Wong | HCW Biologics | 71 | |
| MPH MD | Foghorn Therapeutics | 51 | |
| Allan MD | Foghorn Therapeutics | 49 | |
| Kenneth JD | Century Therapeutics | N/A | |
| John Kelly | Precision BioSciences | 57 | |
| Ruhi MBA | Caribou Biosciences | 50 | |
| Carlos Costa | Foghorn Therapeutics | 52 | |
| Jared MD | Kymera Therapeutics | 60 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 |
Nautilus Biotechnology Leadership Team
Elected by the shareholders, the Nautilus Biotechnology's board of directors comprises two types of representatives: Nautilus Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nautilus. The board's role is to monitor Nautilus Biotechnology's management team and ensure that shareholders' interests are well served. Nautilus Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nautilus Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gwen Weld, Chief Officer | ||
| Parag Mallick, Chief CoFounder | ||
| Sujal Patel, CEO, CoFounder | ||
| Mary Godwin, Senior Operations | ||
| Chris Blessington, Vice Communications | ||
| Subra Sankar, Senior Development | ||
| Kentaro Suzuki, Chief Officer | ||
| Anna Mowry, CFO Treasurer | ||
| Nick Nelson, Chief Development | ||
| Matthew ESQ, General Counsel |
Nautilus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nautilus Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 105.67 M | ||||
| Shares Outstanding | 125.56 M | ||||
| Shares Owned By Insiders | 33.46 % | ||||
| Shares Owned By Institutions | 50.13 % | ||||
| Number Of Shares Shorted | 872.9 K | ||||
| Price To Book | 0.96 X | ||||
| EBITDA | (74.3 M) | ||||
| Net Income | (63.67 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.